Sanofi India Ltd
Sanofi India Ltd (SANOFI) last traded at ₹3,198, a market capitalisation of ₹7,365 crore, on a P/E of 16.7. Over the past 52 weeks the stock has ranged between ₹3,054 and ₹5,200. Sanofi India Ltd last reported results for the quarter ended Dec 2024, with sales of ₹515 crore and net profit of ₹91 crore. Figures are as of 25 Aug 2026 and are not real time.
Sanofi India Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sanofi India Ltd quarterly results
In the quarter ended Dec 2024, sales were ₹515 cr, up 9.8% from ₹469 cr a year earlier. Net profit was ₹91 cr, down 34.1% year on year.
| ₹ crore | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Sales | 515 | 491 | 469 | 511 | 464 | 524 | 515 |
| Expenses | 393 | 377 | 370 | 374 | 348 | 404 | 397 |
| Operating profit | 122 | 114 | 100 | 137 | 116 | 120 | 118 |
| OPM % | 24% | 23% | 21% | 27% | 25% | 23% | 23% |
| Other income | 57 | 82 | 77 | 41 | 21 | 2 | 14 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 |
| Profit before tax | 169 | 186 | 167 | 169 | 127 | 113 | 122 |
| Tax % | 27% | 18% | 18% | 19% | 19% | 27% | 25% |
| Net profit | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| EPS (₹) | 53.43 | 66.04 | 59.87 | 59.39 | 44.87 | 35.74 | 39.70 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sanofi India Ltd annual results
| ₹ crore | Dec 2023 | Dec 2024 |
|---|---|---|
| Sales | 1,996 | 2,013 |
| Operating profit | 488 | 491 |
| OPM % | 24% | 24% |
| Net profit | 603 | 413 |
| EPS (₹) | 262.13 | 179.70 |
TTM is the trailing twelve months to the most recent quarter.
Sanofi India Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -25%
- 10 Years
- 2%
- 5 Years
- -10%
- 3 Years
- -10%
- 1 Year
- -37%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 47%
Sanofi India Ltd shareholding pattern
Promoters held 60.40% at Jun 2026, broadly unchanged since Jun 2025. FIIs 5.69% and DIIs 19.87%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| FIIs | 5.78% | 5.64% | 5.58% | 5.61% | 5.57% | 5.55% | 5.65% | 5.69% |
| DIIs | 22.62% | 22.94% | 23.02% | 23.06% | 22.28% | 21.30% | 21.12% | 19.87% |
| Public | 11.20% | 11.04% | 11.01% | 10.94% | 11.75% | 12.75% | 12.84% | 14.05% |
| No. of shareholders | 66,211 | 66,401 | 68,196 | 66,790 | 71,395 | 75,813 | 75,758 | 80,005 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sanofi India Ltd corporate filings
- Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Kindly refer the attachment.Company Updatehigh impact
Cruxal's analysis: Sanofi India Limited reported a strong second quarter for 2026, highlighted by a 14%…
Read the full analysis - Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed the outcome of its analyst/investor meeting held on August 6…
Read the full analysis - Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has released a routine newspaper publication as part of its regulatory…
Read the full analysis - Kindly refer the attachmentCompany Updatehigh impact
Cruxal's analysis: Sanofi India Limited delivered a robust Q2 2026 performance, with Profit Before Tax (PBT)…
Read the full analysis - Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has submitted a routine disclosure regarding the authorization of Key…
Read the full analysis - Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a disclosure regarding the re-constitution of its board…
Read the full analysis - Kindly refer the attachmentCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Kindly refer the attachmentResulthigh impact
Cruxal's analysis: Sanofi India Limited reported a strong Q2 2026 performance with Profit Before Tax (PBT)…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sanofi India Ltd
Cruxal reads every Sanofi India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.